Acute Myeloid Leukaemia B003

Current RMA Instruments:

Changes from previous Instruments:

ICD Coding

• ICD-10-AM Codes: C92.00-01, C92.30-31, C93.00-01, C94.00-01, C94.20-21, C95.00-01

Brief description

Acute myeloid leukaemia (AML) is a type of cancer that affects the blood and bone marrow. It involves rapid growth of abnormal white blood cells that accumulate in the bone marrow, the blood and other tissues. There is disruption of production of normal blood cells. 'Myeloid' refers to the type of cell the leukaemia starts from. 

Confirming the diagnosis

Diagnosis usually requires bone marrow biopsy.

The relevant medical specialist is haematologist or a haematologist oncologist.

Additional diagnoses covered by these SOPs:

• Acute basophilic leukaemia
• Acute erythroid leukaemia
• Acute granulocytic leukaemia
• Acute megakaryoblastic leukaemia
• Acute monoblastic/monocytic leukaemia
• Acute myeloid leukaemia with defining genetic abnormalities (e.g. NPM1 mutation)
• Acute myeloid leukaemia, myelodysplasia-related genetic abnormalities
• Acute myeloid leukaemia with minimal differentiation, or without maturation or with maturation 
• Acute myeloid leukaemia, not otherwise specified
• Acute myeloblastic leukaemia
• Acute myelocytic leukaemia
• Acute myelogenous leukaemia
• Acute myelomonocytic leukaemia
• Acute myelosclerotic leukaemia
• Acute panmyelosis with myelofibrosis
• Acute promyelocytic leukaemia
• Erytholeukaemia
• Myeloid sarcoma

Conditions not covered by these SOPs

• Acute lymphoblastic leukaemia *
• Chronic lymphocytic leukaemia/small lymphocytic lymphoma *
• Chronic myeloid leukaemia *
• Myeloma *
• Myelodysplastic syndrome *
• Soft tissue sarcoma *

* another SOP applies - the SOP has the same name unless otherwise specified

^# non-SOP condition

Clinical onset

Clinical onset will most likely be at the time of diagnosis.  Early symtpoms are generally vague and non-specific.  A slight back-dating of onset may be possible if symptoms of anaemia or of easy bruising/bleeding were present.

Clinical worsening

AML is a rapidly progressing disease and is typically fatal within weeks or months if left untreated.  The only SoP worsening factor is for inability to obtain appropriate clincial management. Treatment may be curative (particularly in younger subjects) and will generally prolong survival. Any delay in treatment is likely to be detrimental. 

Comments on SOP factors

Undergoing treatment with radioactive iodine or phosphorus does not include diagnostic procedures where these agents as used as tracers.